Brain volumetric alterations accompanied with loss of striatal medium-sized spiny neurons and cortical parvalbumin expressing interneurons in Brd1+/− mice

Per Qvist1,2,3, Simon F. Eskildsen1, Brian Hansen4, Mohammad Baragji1, Steffen Ringgaard5, Jolien Roovers6, Veerle Paternoster1,2,3, Simon Molgaard2, Thomas Juhl Corydon1,2,6, Hans Stødkilde-Jørgensen5, Simon Glerup2, Ole Mors1,3,7, Gregers Wegener8, Jens R. Nyengaard9, Anders D. Børglum1,2,3 & Jane H. Christensen1,2,3

Schizophrenia is a common and severe mental disorder arising from complex gene-environment interactions affecting brain development and functioning. While a consensus on the neuroanatomical correlates of schizophrenia is emerging, much of its fundamental pathobiology remains unknown. In this study, we explore brain morphometry in mice with genetic susceptibility and phenotypic relevance to schizophrenia (Brd1+/− mice) using postmortem 3D MR imaging coupled with histology, immunostaining and regional mRNA marker analysis. In agreement with recent large-scale schizophrenia neuroimaging studies, Brd1+/− mice displayed subcortical abnormalities, including volumetric reductions of amygdala and striatum. Interestingly, we demonstrate that structural alteration in striatum correlates with a general loss of striatal neurons, differentially impacting subpopulations of medium-sized spiny neurons and thus potentially striatal output. Akin to parvalbumin interneuron dysfunction in patients, a decline in parvalbumin expression was noted in the developing cortex of Brd1+/− mice, mainly driven by neuronal loss within or near cortical layer V, which is rich in corticostriatal projection neurons. Collectively, our study highlights the translational value of the Brd1+/− mouse as a pre-clinical tool for schizophrenia research and provides novel insight into its developmental, structural, and cellular pathology.

Schizophrenia (SZ) is a chronic and severe mental disorder that has at its origin structural and functional brain changes1. Whereas our understanding of the genetic and environmental predispositions underlying these changes is increasing2–4, the neuro-molecular and -cellular defects that contribute to disorder initiation and/or progression are yet poorly understood. Epigenetic regulation of neurodevelopment contributes to the structural and functional shaping of the brain2 and has been implicated with the pathophysiology of SZ2. The Bromodomain containing 1 gene (BRD1) encodes a scaffold protein which, through its function in complex with histone modifiers and chromatin remodelers2,4, controls the expression of a comprehensive chromatin interactome enriched...
with genes important in neurodevelopment and mental health. In accordance, BRD1 has been implicated with both brain development and susceptibility to mental illness, including gene-wise significant association in the currently largest SZ genome-wide association study (GWAS) mega-analysis. A SZ case carrying a disruptive BRD1 mutation has furthermore been identified. We have previously reported behavioral, molecular, and neurochemical changes with overall translational relevance to SZ in genetically modified mice with mono-allelic inactivation of Brd1 (Brd1+/− mice). These include cognitive and social deficits, decrease in cortical parvalbumin immunoreactive interneurons, hypersensitivity to psychotomimetic drugs coupled with monoaminergic dysregulation and differential cortical and striatal expression of genes that are enriched for SZ risk. In this research, we investigate the neuropathological impact of reduced Brd1 expression in mice using postmortem 3D MR imaging coupled with histology, immunostaining and regional mRNA marker analysis, and we relate our data to the most recent clinical findings in SZ.

Results

Brain structural changes in Brd1+/− mice. To assess whether reduced Brd1 expression is associated with gross neuroanatomical changes, we subjected adult Brd1+/− (n = 10) and WT (n = 9) mice to high-resolution 3D MR imaging, in combination with deformation-based morphometry analyses. No differences were seen in total grey matter, white matter or overall regional volumes (Table 1). However, Brd1+/− mice were characterized by nominally significant volume reductions in several, particular, sub-cortical brain structures. Most significantly, a ~9% volume reduction was observed in striatum (Table 1 and Fig. 1a, p < 0.01), which was mainly driven by a ~10% reduction in the caudate putamen (CPu) (Table 1 and Fig. 1b, p < 0.01). The adjacent globus pallidus was reduced by ~7% (p = 0.03), amygdala by ~5% (p = 0.01), and a tendency for decreased hippocampal volume was observed (p = 0.07). In support of these findings, striatal and amygdaloid volume reductions were observed in both hemispheres independently (CPu: left, p = 0.04; right, p = 0.05; amygdala: left, p = 0.03; right, p = 0.03). Further supporting volume loss, a stereological estimate in fixed tissue from an independent group of mice (7 WT and 6 Brd1+/−) showed a comparable ~11% total CPu volume reduction in Brd1+/− mice compared to WT mice (Fig. 1c, p < 0.01, Table 2). Although total brain volume did not differ between Brd1+/− and WT mice (Table 1), a moderate to strong positive correlation was observed between total brain volume and volumes of most regions, structures and substructures excluding the ventricles (Fig. 1d). Furthermore, a positive moderate correlation was observed between ventricular volume and the volume of the hippocampus, amygdala, and CPu – in accordance with all of these structures being reduced in size in Brd1+/− mice. On the other hand, a considerable negative correlation was apparent between ventricle-, and CPu volume and corticospinal tract volume (Fig. 1d). In the cerebral cortex, structural alterations were observed in the occipital lobe, where a significant volume reduction was noted in Brd1+/− mice compared to WT mice (Table 1, p = 0.02). Assessment of cortical thickness further revealed nominal significant thinning in this region along with thickening of the sensorimotor cortex (Fig. 1e).

Loss of CPu neurons in Brd1+/− mice. To assess whether a potential cellular underpinning of the structural change in CPu, we performed a stereological estimate of total CPu neurons in fixed tissue from an independent group of mice (7 WT and 6 Brd1+/−). In line with reduced CPu volume in Brd1+/− mice, a significant (~20%) reduction in striatal neurons was seen in Brd1+/− compared to WT mice (Fig. 1f, p < 0.01, Table 2). To assess the molecular implications of reduced Brd1 expression on striatal cells, we utilized previously published RNAseq data from the dorsal striatum of adolescent +/+ mice and WT mice and performed cell specific expression analysis (CSEA). Non-surprisingly, differentially expressed genes (DEGs) were strongly enriched with genes specifically expressed in striatal neurons, namely medium-sized spiny neurons (MSN)s (Fig. 1g, Dopamine receptor 2 expressing (D2+) MSNs: q = 8.54E-12, and Dopamine receptor 1 expressing (D1+) MSNs: q = 3.61E-05). Indicating that cellular loss is present already in adolescent Brd1+/− mice, DEGs overlapping the MSN enriched gene lists were exclusively downregulated in Brd1+/− mice, suggesting that this subset of DEGs may not reflect altered gene transcription, but rather a change in cell composition. Only neuronal mRNA markers were over-represented among striatal DEGs whereas glial-, and oligodendrocyte mRNA markers where not. Notably, the decrease in markers for D2+ MSNs was moderately larger than that for D1+ MSNs (Fig. 1h, p < 0.01). Although not significantly enriched in the DEG set, markers for cholinergic, but not GABAergic interneurons, were additionally decreased in Brd1+/− mice (Fig. 1h).

Reduced number of parvalbumin expressing interneurons in Brd1+/− mice. Although no gross structural abnormalities were identified in the frontal cortex of Brd1+/− mice in this study, we have previously reported cortical cellular pathologies, including a significant reduction of parvalbumin immunoreactive (PV+) interneurons in the anterior cingulate cortex (aCC) of Brd1+/− mice. Altered levels of interneuron mRNA markers and/or immunoreactivity in the adolescent brain may reflect improper neurodevelopment (e.g., impaired proliferation of neuronal progenitor cells, migration defects or GABA interneuron subtype alteration), neuronal loss by degeneration and/or transcriptional regulation. PV+ interneurons are preferentially ensheathed by perineuronal nets consisting of specialized extracellular matrix components which bind the lectin, Vicia Villosa Agglutinin (VVA). Hence, VVA staining was used as a reliable marker for visualizing the specific neuronal subpopulation of cells potentially expressing PV (Fig. 2a, top). Confirming a reduction of PV+ immunoreactive aCC interneurons, we found a ~30% decrease in PV+ neurons in adolescent Brd1+/− compared to WT mice (Fig. 2a, p < 0.01, Table 2). Similarly, we found a ~23% reduction in VVA+ cells (Fig. 2a, p < 0.01, Table 2) and a ~30% decrease in cells expressing both PV and VVA (Fig. 2a, p < 0.01, Table 2), indicating that the reduction in PV+ immunoreactive neurons in adolescent Brd1+/− mice is primarily, but not exclusively, due to an absence of neurons. Interestingly, by assessing the regional number of VVA+ neurons in the cortical layers of the aCC, it became apparent that the loss of PV+ interneurons was not equally distributed across aCC tissue, but predominantly localized to the centermost region corresponding to cortical layer V (Fig. 2b, 2-way ANOVA, genotype
| Region          | Structure                        | Sub-structure                        | Average (mm³) | Change in absolute volume (%) | Groupwise difference | p value |
|-----------------|----------------------------------|---------------------------------------|---------------|-------------------------------|----------------------|---------|
| Cerebral grey   | Cerebral Cortex                  | Frontal Cortex                        | 46.0 ± 0.9    | 44.7 ± 0.8                    | −2.8 ± 0.8           | 0.30    |
|                 |                                  | Occipital Cortex                      | 6.5 ± 0.2     | 5.9 ± 0.2                     | −9.8 ± 0.2           | 0.02    |
|                 |                                  | Parieto-temporal Cortex               | 80.3 ± 2.0    | 78.3 ± 2.2                    | −2.5 ± 2.0           | 0.51    |
|                 |                                  | Entorhinal Cortex                     | 10.1 ± 0.7    | 9.6 ± 0.6                     | −5.2 ± 0.5           | 0.55    |
|                 |                                  |                                      | 143.0 ± 3.3   | 138.5 ± 3.6                   | −3.1 ± 3.7           | 0.37    |
|                 | Hippocampus                      | Hippocampus Proper                    | 24.0 ± 0.4    | 22.7 ± 0.5                    | −5.5 ± 0.5           | 0.07    |
|                 |                                  | Dentate Gyrus                         | 4.6 ± 0.3     | 4.1 ± 0.1                     | −10.8 ± 0.4          | 0.14    |
|                 |                                  | Stratum Granulosum                    | 1.1 ± 0.0     | 1.0 ± 0.0                     | −0.0 ± 0.0           | 0.11    |
|                 |                                  |                                      | 29.7 ± 0.7    | 27.8 ± 0.7                    | −6.4 ± 0.7           | 0.07    |
|                 | Amygdala                         |                                       | 16.3 ± 0.2    | 15.5 ± 0.2                    | −5.3 ± 0.3           | 0.01    |
|                 | Striatum                         | Caudate Nucleus/Putamen               | 20.5 ± 0.5    | 18.4 ± 0.5                    | −10.5 ± 0.5          | <0.01   |
|                 |                                  | Fundus of Striatum                    | 0.2 ± 0.0     | 0.2 ± 0.0                     | 0.9 ± 0.0            | 0.90    |
|                 |                                  | Nucleus Accumbens                     | 4.4 ± 0.2     | 4.3 ± 0.1                     | −3.6 ± 0.5           | 0.45    |
|                 |                                  |                                      | 25.1 ± 0.6    | 22.8 ± 0.5                    | −9.1 ± 0.5           | 0.01    |
|                 | Subiculum (pre-para)             |                                       | 0.3 ± 0.1     | 0.4 ± 0.1                     | 28.9 ± 0.8           | 0.38    |
|                 | Globus Pallidus                  |                                       | 3.2 ± 0.1     | 3.0 ± 0.1                     | −6.9 ± 0.3           | 0.03    |
|                 | Thalamus                         |                                       | 18.4 ± 0.4    | 17.6 ± 0.5                    | −4.1 ± 0.2           | 0.27    |
|                 | Hypothalamus                     |                                       | 12.1 ± 0.3    | 11.6 ± 0.4                    | −3.7 ± 0.3           | 0.39    |
|                 | Mammillary Bodies                |                                       | 0.6 ± 0.0     | 0.6 ± 0.1                     | 0.1 ± 1.0            | 1.00    |
|                 | Medial Septum                    |                                       | 1.5 ± 0.1     | 1.4 ± 0.1                     | −3.0 ± 0.6           | 0.64    |
|                 | Lateral Septum                   |                                       | 3.9 ± 0.2     | 3.8 ± 0.2                     | −2.5 ± 0.7           | 0.76    |
|                 | Basal Forebrain                  |                                       | 5.0 ± 0.1     | 4.9 ± 0.2                     | −1.8 ± 0.8           | 0.68    |
|                 | Bed Nucleus of Stria Terminals   |                                       | 1.5 ± 0.1     | 1.5 ± 0.1                     | 0.2 ± 0.8            | 0.98    |
|                 |                                  |                                      | 260.6 ± 5.7   | 249.5 ± 5.7                   | −4.3 ± 0.1           | 0.19    |
| Cerebral white  | Anterior Commissure: pars anterior|                                       | 1.7 ± 0.1     | 1.5 ± 0.0                     | −9.5 ± 0.0           | 0.01    |
|                 | Anterior Commissure: pars posterior|                                     | 0.5 ± 0.0     | 0.5 ± 0.0                     | −1.9 ± 0.0           | 0.80    |
|                 | Posterior Commissure             |                                       | 0.1 ± 0.0     | 0.1 ± 0.0                     | −4.5 ± 0.3           | 0.43    |
|                 | Cerebral Peduncle                |                                       | 2.6 ± 0.1     | 2.5 ± 0.1                     | −4.3 ± 0.3           | 0.37    |
|                 | Corpus Callosum                  |                                       | 17.1 ± 0.4    | 16.5 ± 0.2                    | −3.1 ± 0.8           | 0.18    |
|                 | Fasciculus Retrolflexus          |                                       | 0.3 ± 0.0     | 0.3 ± 0.0                     | 0.8 ± 0.8            | 0.87    |
|                 | Fimbria                          |                                       | 3.5 ± 0.1     | 3.2 ± 0.1                     | −7.4 ± 0.2           | 0.12    |
|                 | Fornix                           |                                       | 0.8 ± 0.1     | 0.7 ± 0.1                     | −2.8 ± 0.7           | 0.79    |
|                 | Habenular Commissure             |                                       | 0.0 ± 0.0     | 0.0 ± 0.0                     | −11.0 ± 0.0          | 0.38    |
|                 | Internal Capsule                 |                                       | 3.0 ± 0.1     | 2.8 ± 0.1                     | −5.7 ± 0.5           | 0.15    |
|                 | Mammillothalamic Tract           |                                       | 0.36 ± 0.0    | 0.3 ± 0.0                     | −2.1 ± 0.7           | 0.74    |
|                 | Optic Tract                      |                                       | 1.9 ± 0.1     | 1.9 ± 0.1                     | −0.4 ± 0.1           | 0.94    |
|                 | Stria Medullaris                 |                                       | 0.8 ± 0.0     | 0.8 ± 0.0                     | −2.7 ± 0.7           | 0.62    |
|                 | Stria Terminals                  |                                       | 1.0 ± 0.0     | 1.0 ± 0.0                     | −5.4 ± 0.5           | 0.25    |
|                 |                                  |                                      | 33.4 ± 0.6    | 32.1 ± 0.5                    | −4.1 ± 0.1           | 0.10    |
| Olfactory       | Olfactory Bulbs                  |                                       | 29.2 ± 0.5    | 29.4 ± 0.7                    | 0.5 ± 0.8            | 0.88    |
|                 | Olfactory Tubercle               |                                       | 4.1 ± 0.1     | 3.9 ± 0.1                     | −3.4 ± 0.4           | 0.45    |
|                 | Lateral Olfactory Tract          |                                       | 1.6 ± 0.1     | 1.6 ± 0.1                     | −3.3 ± 0.4           | 0.48    |
|                 |                                  |                                      | 34.9 ± 0.6    | 34.9 ± 0.9                    | −0.1 ± 0.6           | 0.96    |
| Cerebellum      | Arbor Vita of Cerebellum         |                                       | 9.6 ± 0.3     | 9.7 ± 0.3                     | 1.1 ± 0.1            | 0.81    |
|                 | Cerebellar Cortex                |                                       | 47.8 ± 1.4    | 48.5 ± 1.3                    | 1.5 ± 0.7            | 0.70    |
|                 | Cerebellar Peduncle: Inferior    |                                       | 1.0 ± 0.1     | 0.9 ± 0.1                     | −11.9 ± 0.1          | 0.15    |
|                 | Cerebellar Peduncle: Middle      |                                       | 1.5 ± 0.1     | 1.4 ± 0.0                     | −5.3 ± 0.2           | 0.22    |
|                 | Cerebellar Peduncle: Superior    |                                       | 0.9 ± 0.1     | 0.9 ± 0.1                     | −0.1 ± 0.1           | 0.99    |
|                 |                                  |                                      | 60.8 ± 1.6    | 61.4 ± 1.6                    | 1.1 ± 0.7            | 0.78    |
|                 | Continued                        |                                       |               |                               |                      |         |
on previously published aCC DEGs reported in struct and face validity to SZ in order to illuminate potential structural- and neuronal pathologies of the disorder.

WT mice (Fig. 2c). To investigate if healthy controls)1, which particularly identify subcortical structural abnormalities in SZ (Fig. 3). Importantly, however, whereas SZ cases are characterized by volume reduction of the ventral striatum (accumbens), the striatal changes. However, medication exposure, patient heterogeneity and the temporal gap between in vivo progression27. Here we assess brain morphometry and neuronal mRNA markers in an animal model with con-

Table 1. 3D MR imaging-based brain volumetric analysis. 3D MR imaging coupled with deformation-based morphometry analyses of differences in absolute cerebral volumes (whole brain, brain regions, brain structures and sub-structures) of 15 weeks old Brd1+/− mice (n = 9) compared to WT mice (n = 10). The change in volume was calculated as the percentage change between the mean volume of the WT group and the mean volume of the Brd1+/− group. Nominally significant groupwise differences are in bold.

effect, p < 0.001, post hoc test (layer V) p < 0.01). Further pointing to altered function of neurons in layer V, CSEA on previously published aCC DEGs reported in Brd1+/− mice15 were overall significantly enriched with markers for layer Va cells (Fig. 2c, q = 1.759e-07), whereas no enrichment was seen in markers for layer Vb or layer VI neurons. mRNA markers for layer Va cells were furthermore predominantly decreased in Brd1+/− mice compared to WT mice (Fig. 2c). To investigate if Brd1+/− mice show early signs of interneuron loss, we additionally assessed a selection of cortical interneuron mRNA markers in newborn (P0)-, and juvenile (P21) mice. Surprisingly, in newborn mice, including volumetric changes in striatum and other subcortical structures. Collectively, mice15 were overall significantly enriched with markers linked to genetic, prenatal and environmental factors25 as well as post-onset progression26 may contribute to these changes. However, medication exposure, patient heterogeneity and the temporal gap between in vivo imaging and neuropathological studies complicates the interpretation of these changes in relation to disorder initiation and progression25. Here we assess brain morphometry and neuronal mRNA markers in an animal model with construct and face validity to SZ in order to illuminate potential structural- and neuronal pathologies of the disorder.

Brd1+/− mice are characterized by behavioral and neurochemical alterations that implicates widespread brain impairments15, including monoaminergic dysregulation and psychotomimetic drug sensitivity. Using an MR imaging based approach, we find volumetric changes in brain tissues that are functionally linked to reported deficits in Brd1+/− mice, including volumetric changes in striatum and other subcortical structures. Collectively, our results compare to the findings of the presently largest SZ MRI mega-analysis (2 028 individuals with SZ and 2 540 healthy controls), which particularly identify subcortical structural abnormalities in SZ (Fig. 3). Importantly, however, whereas SZ cases are characterized by volume reduction of the ventral striatum (accumbens), the striatal volume loss in Brd1+/− mice, is seen in the dorsal part (caudate/putamen) (Figs 1b and 3) as has previously been reported in medication free cases19. Dorsal striatal activity has been shown to correlate with positive symptoms and sub-structures) of 15 weeks old Brd1+/− mice, we found a ~40% reduction in Cck mRNA levels were normal in newborn mice, including early signs of interneuron loss, we additionally assessed a selection of cortical interneuron mRNA markers in newborn (P0)-, and juvenile (P21) mice. Surprisingly, in newborn mice, including volumetric changes in striatum and other subcortical structures. Collectively, mice15 were overall significantly enriched with markers linked to genetic, prenatal and environmental factors25 as well as post-onset progression26 may contribute to these changes. However, medication exposure, patient heterogeneity and the temporal gap between in vivo imaging and neuropathological studies complicates the interpretation of these changes in relation to disorder initiation and progression25. Here we assess brain morphometry and neuronal mRNA markers in an animal model with construct and face validity to SZ in order to illuminate potential structural- and neuronal pathologies of the disorder.

Brd1+/− mice are characterized by behavioral and neurochemical alterations that implicates widespread brain impairments15, including monoaminergic dysregulation and psychotomimetic drug sensitivity. Using an MR imaging based approach, we find volumetric changes in brain tissues that are functionally linked to reported deficits in Brd1+/− mice, including volumetric changes in striatum and other subcortical structures. Collectively, our results compare to the findings of the presently largest SZ MRI mega-analysis (2 028 individuals with SZ and 2 540 healthy controls), which particularly identify subcortical structural abnormalities in SZ (Fig. 3). Importantly, however, whereas SZ cases are characterized by volume reduction of the ventral striatum (accumbens), the striatal volume loss in Brd1+/− mice, is seen in the dorsal part (caudate/putamen) (Figs 1b and 3) as has previously been reported in medication free cases19. Dorsal striatal activity has been shown to correlate with positive symptoms such as delusions and hallucinations28. It serves as the primary gateway of the basal ganglia and play key roles in motor control as well as learning, memory and decision-making29, especially in action selection and initiation through the convergence of corticostriatal and thalamostriatal afferents30. Noteworthy in this regard, decreased.
Figure 1. Assessment of brain structural changes using 3D structural magnetic resonance imaging, cell-type specific expression analysis of striatal differentially expressed genes, and estimation of striatal volume and neuron numbers using stereology in Brd1+/− and WT mice. (a) Coronal and sagittal MRI slices showing the nominally significant differences in absolute volume of subcortical structures between 15 weeks old Brd1+/− (n = 10) and WT (n = 9) mice. The percentage change in brain structure volume is indicated by the color bar on the left. (b) Horizontal, sagittal and coronal MRI slices showing local deformations between the average of Brd1+/− and WT mice within striatum. The percentage voxel-based change in volume is indicated by the color bar on the left. (Red color marks Brd1+/− mice larger and blue color marks Brd1+/− smaller). (c) Stereological estimate on CPu volume in histological samples from an independent batch of 15 weeks old mice, further supports a significant volume loss in Brd1+/− (n = 6) compared to WT (n = 7) mice (t test, p = 0.0069). (d) A heat map of the correlation coefficient matrix for volumes in all brain regions, structures, and sub-structures in Brd1+/− and WT mice. The color scale on the left side shows the strength of the correlation using white
(no correlation), blue (negative correlation), and red (positive correlation). (e) Illustration of cortical surface showing the localization of groupwise differences in cortical thickness. Only uncorrected p values are presented. Top: t-map (red color marks Brd1+/− mouse thicker and blue color marks Brd1−/− thinner). Bottom: t-map with threshold cutoff at p < 0.05. (f) Stereological estimation of total number of CPu neurons show a significant reduction in 15 weeks old Brd1+/− (n = 6) compared to WT (n = 7) mice (t test, p = 0.012). White arrows points to neurons, whereas black arrow points to glia. (g) Cell specific expression analysis (CSEA) of DEGs identified in dorsal striatum of 8 weeks old Brd1−/− mice. Black bars show the Fisher’s Exact Benjamini-Hochberg (BH) corrected p values (−log10(q value)) of overlap between DEGs and 27 broad and specific cell type gene sets (at CSEA specificity threshold set to 0.0001). Red bars show the relative contribution of downregulated DEGs to that significance. Enrichments were recorded as statistically significant at q < 0.05 indicated by the red dotted line. (h) Log2 fold change in expression of mRNA markers of various striatal cell types. Red dotted line indicates groupwise mean for markers for D1+ and D2+ MSNs, respectively. The decrease in markers for D2+ MSNs was moderately larger than that for D1+ MSNs (t test, p = 0.008). *p < 0.05; **p < 0.01; ***p < 0.001.

CPu volume correlate negatively with corticospinal tract volume and thickening of the somatosensory cortex in Brd1+/− mice. Although there is a large degree of functional homology between the rodent and primate striatum, a direct comparison is complicated by differences in striatal organization31, cellular compositions32, and efferent connectivity33. Striatal volume loss may reflect either neuronal loss, shrinkage of neuron cell bodies and/or non-neural changes, such as loss of glial components. The neuronal types of striatum includes MSNs, which constitute the majority of neurons (>90% in rodents)34,35, cholinergic interneurons (1–3%)36 and various types of GABAergic interneurons37. We find an overall decrease in striatal neurons, with decreased mRNA markers for both MSNs and cholinergic interneurons. MSNs exist as two approximately equally-sized populations based on axonal projections and expression of dopamine receptor subtypes (D2+ or D1+) which have distinctive linkages to intracellular signaling cascades and targets, leading to fundamentally different cellular responses to extracellular dopamine. Namely, activation of dopamine receptor D1 facilitates ATP to cAMP conversion and thus increased cAMP mediated signaling, whereas activation of dopamine receptor D2 inhibits this process38. In line with previously reported over-activation of cAMP mediated signaling in the dorsal striatum of Brd1+/− mice15, we find a larger decrease in D2+ than D1+ mRNA markers. D1+ MSNs project via the direct pathway, and D2+ MSNs via the indirect pathway to the substantia nigra pars reticulata38 where they control the activity of afferents to the thalamus, and consequently produce opposing influence on motor output systems39. Activation of the direct pathway promotes motor activity whereas stimulation of the indirect pathway inhibits motor activity40. The imbalance in striatal D2+/D1+ MSNs suggested in the present study thus might explain the increased sensitivity towards the psychomotor stimulatory effects of cocaine and phencyclidine observed in Brd1+/− mice15. Striatal cholinergic interneurons, however, differentially modulate MSN excitability dependent on dopamine tone39, thus complicating the interpretation. Although the largest structural change was detected in the dorsal striatum, volume reductions were similarly noted in neighboring globus pallidus, and amygdala where the cellular compositions are markedly different from that of striatum (i.e. amygdala is composed of 80% glutamatergic spiny principal neurons and GABAergic interneurons41). Assessment of cellular pathologies in these brain tissues in Brd1+/− mice is thus warranted.

Prefrontal cortex (PFC) dysfunction has been implicated in SZ pathology, across symptom domains42–45, and alterations of the inhibitory PFC circuitry preferentially involving PV+ interneurons, are among the most robust findings46. In agreement with previously reported reduction in the number of PV immunoreactive interneurons in aCC in Brd1+/− mice, we find a similar reduction using a different staining method and a different stereological approach. Moreover, we demonstrate the source of reduction primarily lies in reduced number of neurons and not in loss of immunoreactivity. Additionally, the reduction is most prominent in the centermost part of aCC, corresponding to layer V. This is supported by assessment of RNAseq data from the aCC region in Brd1+/− mice, showing that DEGs cluster particularly in genes expressed in layer Va. Intriguingly, cortical projections to striatum originates exclusively in cortical layer V47–49. Finally, through assessment of interneuron mRNA markers in cortical tissue from newborn and juvenile Brd1+/− mice along with RNAseq data from aCC in adolescent mice, we suggest that PV dysfunction might not be restricted to aCC, and that the dysfunction could be progressive and thus, likely neurodevelopmental in its origin. However, further investigations are warranted to delineate the neurodevelopmental impact of reduced Brd1 expression.

Despite recent advances in neuro-genetics, functional neuro-science, and profiling of the brain structural abnormalities in SZ, there has only been limited progress in understanding the pathophysiology and the development of effective therapies. Whereas studies in patients are largely limited to in vivo neuroimaging and post-mortem examination, the much needed translation of disease pathology into mouse models has proven to be challenging, primarily due to the complex genetic architecture of SZ50. In the present study, we assess cellular and structural changes in a well characterized genetically modified mouse model that incorporates SZ genetic risk at three levels: allelic, chromatin interactomic, and brain transcriptomic51. We identify volumetric changes in brain structures that are largely overlapping with structural changes reported in the presently largest SZ MR imaging mega-analysis and functionally linked to SZ symptomatology. Intriguingly, we demonstrate that the striatal volume reduction is caused by a general loss of striatal neurons, likely differentially implicating D1+ and D2+ MSNs, thus presumably resulting in overall altered striatal output. Potentially coupled to this defect, we find indication of developmental loss of cortical PV+ neurons in cortical layer V that is rich with corticostratial projection neurons.

Collectively, our study highlights the translational value of the Brd1+/− mouse as a pre-clinical tool for SZ research and provides novel insight into its structural and cellular pathology.
Table 2. Volumes and cell numbers in WT and Brd1<sup>+/-</sup> mice. CPu: caudate putamen, aCC: anterior cingulate cortex, PV: parvalbumin, VVA: Vicia Villosa Agglutinin, SD: standard deviation, CV: coefficient of variation, CE: coefficient of error.

|        | WT            |          |          |          | WT        |          |          |          |          | p value |
|--------|---------------|----------|----------|----------|-----------|----------|----------|----------|----------|---------|
|        | Goup mean    | SD       | CV       | CE/SD    | Goup mean | SD       | CV       | CE/SD    |          |         |
| CPu (µm<sup>3</sup>) | 10.90       | 0.70     | 0.06     |          | 9.70      | 0.59     | 0.06     |          | <0.01    |         |
| CPu (neurons) | 866016       | 90787    | 0.14     | 0.16     | 527479    | 84378    | 0.16     | 0.12     | <0.01    |         |
| aCC (PV+ neurons) | 9481       | 1639     | 0.17     | 0.10     | 6294      | 1536     | 0.24     | 0.05     | <0.01    |         |
| aCC (VVA+ neurons) | 9837       | 1600     | 0.16     | 0.11     | 7206      | 1334     | 0.19     | 0.09     | <0.01    |         |
| aCC (PV+ and neurons) | 9375     | 1633     | 0.17     | 0.10     | 6157      | 1556     | 0.25     | 0.05     | <0.01    |         |

Methods and Materials

Animals. A mouse line heterozygous for a targeted deletion in the Brd1 gene was generated by TaconicArtemis GmbH (Cologne, Germany) on a congenic C57BL/6NTac genetic background as previously described<sup>34</sup>. Mice were group housed 2–8 mice per cage in Macrolon (type II) cages with standard sawdust bedding and standard rodent food and tap water available ad libitum. The cages were enriched with igloos, wooden chew blocks and paper for nesting. Mice were kept on a 12:12 hours light–dark cycle and maintained on 23 ± 2°C temperature. Tail biopsies were collected for Polymerase Chain Reaction (PCR) based genotyping after weaning (P21). Only male mice were used in the study. All studies were carried out in accordance with Danish legislation, and permission for the experiments was granted by the animal welfare committee, appointed by the Danish Ministry of Food, Agriculture and Fisheries – Danish Veterinary and Food Administration.

3D structural magnetic resonance imaging (MRI) and deformation-based analysis. Adult male mice (15 weeks old, 9 WT and 10 Brd1<sup>+/-</sup>) were carefully euthanized by cervical dislocation and immobilized in the MRI scanner. A Pilot MRI scan showed no structural damage inflicted by this method compared to scans of mice euthanized by lethal injection. Initially, 9 MRI datasets (4 WT and 5 Brd1<sup>+/-</sup>) were acquired on a 9.4T Agilent small-bore scanner (Agilent, Santa Clara, CA, USA) using a 20-mm surface coil (RAPID Biomedical Rimpar, Germany) for signal reception. The images were acquired using a 3D fast gradient echo sequence with repetition time (TR) = 13.7 ms, echo time (TE) = 6.9 ms, flip angle = 20°, matrix size = 400 × 400 × 400, field-of-view = 4.0 × 4.0 × 2.0 cm, spatial resolution = 100 × 100 × 50 µm (highest resolution in coronal direction), number of averages = 4, and acquisition time = 2:26 hours.

Following a coil malfunction, the remaining 10 MR datasets were acquired using a Bruker Biospec 9.4T small-bore system equipped with a 25 mm quadrature volume coil. Here, the scan protocol was adjusted to provide similar image quality as obtained with the higher sensitivity surface coil: fast gradient echo, TR = 4 ms, TE = 6.9 ms, flip angle = 40°, matrix size = 325 × 200 × 256, field-of-view = 2.6 × 1.6 × 1.0 cm, spatial resolution = 80 × 80 × 40 µm (highest resolution in coronal direction), number of averages = 50, and acquisition time = 3:57 hours.

Image analysis. MR images were corrected for B1 inhomogeneity using N3<sup>2</sup> and denoised using a non-local means filter<sup>32</sup>. Brain masks were manually constructed using ITK-SNAP (www.itksnap.org)<sup>33</sup>. Then images were linearly and non-linearly<sup>34</sup> registered to a neuroanatomical atlas of the C57BL/6J mouse with 62 different, labelled regions<sup>35</sup>. Region of interest labels were subsequently transformed and resampled to scanner native space using the calculated deformation fields and affine transformations for calculation of individual regional volumes.

Cortical thickness analysis. Cortical thickness was calculated as previously described<sup>36</sup>. Briefly, Laplace’s equation, with a fixed boundary condition that differed at the inner and outer surfaces, was solved using the spatial transformations determined previously by image registration to identify corresponding surface points for each mouse.

Tissue preparation. For histological analysis of caudate putamen (CPu) tissue, an independent batch of 15 weeks old male mice (7 WT and 6 Brd1<sup>+/-</sup>) were used and anterior cingulate cortex (aCC) immunohistochemistry was performed on 8 weeks old mice (8 WT and 6 Brd1<sup>+/-</sup>). Mice were deeply anesthetized with isoflurane. Transcardial brain perfusion fixation was initiated using Cardioplex solution followed by 4% formaldehyde via the left ventricle. Brains were dissected and immersed in 4% formaldehyde for 24 hours and then cryoprotected in sucrose solution (30% w/v) for 48 hours followed by snap-freezing. Brains were molded in Tissue-Tek (Sakura, Tokyo, Japan).

Histology. Brains were sectioned (40 µm, coronally from Bregma +1.94 mm to −2.46 mm) on a Microm HM355 cryostat (Microm International GmbH, Walldorf, Germany) and sections chosen by systematic sampling. Every 6th section was sampled for Toluine Blue staining. Sections were assessed under an Olympus BX50 light microscope equipped with a Prior motorized stage, a Heidenhain microcator, Olympus UPlanSApo 60x oil lens (NA = 1.35) and an Olympus DP70 digital camera controlled by newCAST (Visiopharm, Hoersholm, Denmark) software.
Stereological estimate of CPu volume. The 2D nucleator and the Cavalieri estimator were combined for unbiased volume estimation of left CPu in the stained sections using the following equation: $V_{(CPu)} = T \cdot \sum \text{Area}(CPu)$. $T$ is the distance between sections and $\text{Area}(CPu)$ is the summed areas of CPu estimated by the 2D nucleator.

Stereological estimate of CPu neurons. The total number of CPu neurons was estimated by the optical fractionator. The step lengths in the x- and y-direction were 400 $\mu$m, and the area of the two-dimensional unbiased counting frame was 2 000 $\mu$m$^2$. Disector height and location was decided by the z-axis analysis and counts were performed between $-5$ to $-15$ $\mu$m in the z-direction. CPu neurons were identified among toluene blue outlined neurons.

Figure 2. Stereological estimation of difference in numbers of anterior cingulate cortex (aCC) neurons expressing parvalbumin and the lectin, Vicia Villosa Agglutinin, cell-type specific expression analysis of differentially expressed genes detected in aCC, and difference in expression of interneuron markers in cortex at three developmental stages between WT and Brd1$^{+/−}$ mice. (a) Estimation of aCC neurons stained positive for PV$^+$ and VVA$^+$ in tissue sections from 8 weeks old Brd1$^{+/−}$ (n = 6) and WT (n = 8) mice reveals a reduction in cells expressing PV (t test, $p = 0.008$), VVA (t test, $p = 0.003$) and both (t test, $p = 0.0025$) in Brd1$^{+/−}$ mice. (b) Illustration of image sampling in aCC. 7 image z-stacks were acquired from each hemisphere in 4 different tissue sections per animal. Z-stacks were approximately distributed across cortical layers as illustrated above (3 stacks in layer I-III, 3 in layer V and 1 in layer VI). Reduced number of neurons is restricted to tissue corresponding to cortical layer V (2-way ANOVA, genotype effect, $p < 0.001$, post hoc test (layer V) $p < 0.01$). (c) Cell specific expression analysis (CSEA) of DEGs identified in aCC of 8 weeks old Brd1$^{+/−}$ mice. For further details see legend to Fig. 1g (d) Log2 fold change (Log2FC) in expression of interneuron markers between WT and Brd1$^{+/−}$ mice in whole cortex (newborns (P0), n = 6 in each group, (red)), frontal cortex (juvenile (P21), n = 7 in each group, (blue)), and aCC (adolescent (P56–63), n = 10 in each group, (black)). ** $p < 0.01$. 

Stereological estimate of CPu volume. The 2D nucleator and the Cavalieri estimator were combined for unbiased volume estimation of left CPu in the stained sections using the following equation: $V_{(CPu)} = T \cdot \sum \text{Area}(CPu)$. $T$ is the distance between sections and $\text{Area}(CPu)$ is the summed areas of CPu estimated by the 2D nucleator.

Stereological estimate of CPu neurons. The total number of CPu neurons was estimated by the optical fractionator. The step lengths in the x- and y-direction were 400 $\mu$m, and the area of the two-dimensional unbiased counting frame was 2 000 $\mu$m$^2$. Disector height and location was decided by the z-axis analysis and counts were performed between $-5$ to $-15$ $\mu$m in the z-direction. CPu neurons were identified among toluene blue outlined neurons.
cells by their characteristic large cytoplasm, large nucleus and prominent nucleolus. The total number of neurons, N(neu), in the CPu was estimated using the optical fractionator:

\[
N(neu) = \frac{(1/ssf) \cdot (1/asf) \cdot (1/hsf) \cdot \sum Q(neu)}{v(dis) \cdot V(aCC)},
\]

where ssf, asf and hsf are referred to as section sampling sample fraction, area sampling fraction and height sampling fraction, respectively.

**Cell-type specific expression analysis and subtype mRNA marker analysis.** Cell type–specific enrichment for nominally significant differentially expressed genes (DEGs) previously reported in RNAseq studies on tissue micropunches from dorsal striatum and aCC in 8 weeks old Brd1\(^{+/–}\) mice\(^{15}\) was performed using the cell specific expression analysis (CSEA) tool (http://genetics.wustl.edu/jdlab/csea-tool-2/). This tool contains cell type–specifically expressed genes derived from a translational profiling approach that have identified murine transcriptomes from specific, marker-defined cellular subpopulations\(^57\). We assessed each set of DEGs (dorsal striatum and aCC) for enrichment of 27 broad and specific cell type gene sets (at CSEA specificity threshold set to 0.0001). Enrichments were regarded as statistically significant at Benjamini-Hochberg corrected p value (q value) < 0.05.

**Immunohistochemistry.** Brains were sectioned (40\(\mu\)m, coronally from Bregma 1.5 mm to 0.5 mm) as described above. Sections were washed (3 \(\times\) 10 min) in TBS containing 0.3% Triton X-100 (TBS buffer), treated and incubated with target retrieval solution (Dako, Glostrup, Denmark) for 20 minutes at 80 \(^\circ\)C and washed again (5 \(\times\) 15 min). Sections were rinsed and blocked with Donkey anti-mouse Fab fragments (1:10) (Jackson Immunoresearch, West Grove, USA) for 2 hours followed by 5 days of incubation with primary antibody Oyster 550-labeled (Synaptic Systems, Göttingen, Germany) directed towards parvalbumin (PV). Sections were then incubated with 488-conjugated Vicia Villosa Agglutinin (VV A) lectin (Vector Laboratories, Burlingame, USA) and washed (6 \(\times\) 10 min) in TBS buffer and (1 \(\times\) 10 min) in 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, Missouri, USA). Finally, the sections were mounted on glass slides and coverslipped with Prolong Diamond mounting media (Thermofisher Scientific, Waltham, USA). The quality of staining of PV+ and VVA+ interneurons was evaluated using Zeiss LSM710/780 laser-scanning confocal microscopes controlled by ZEN 2009/2011 software (Carl Zeiss, Jena, Germany), respectively, as previously described\(^58\), 3-dimensional confocal images were taken by collecting stack images (135 \(\mu\)m \(\times\) 135 \(\mu\)m) with a z-plane step size of 1.5 \(\mu\)m throughout the section depth giving a total of 14–16 stacks per image. A total of 14 z-stacks were acquired per brain section (7 z-stack per hemisphere distributed across cortical layer I-IV, V and VI (see Fig. 2b) with 4 brain sections included per animal. The VVA+ and PV+ cells were counted independently and combined according to the following criteria: (1) Well visible DAPI-stained nucleus; (2) PV staining surrounding the DAPI-stained nucleus for PV+ cells (3) VVA staining surrounding the cell body. The total number of PV+, VVA+ and PV+/VVA+ neurons, N(cells, aCC), in the aCC was estimated using the equation:

\[
N(cells, aCC) = \frac{\sum Q^*(cells)}{\sum V(dis)} \cdot V(aCC),
\]

where Q* (cells) is the number of cells counted in optical disector, v(dis) is volume of dissectors and V(aCC) is total volume of aCC.

**Quantitative reverse transcription-PCR.** Whole cortices were sampled from newborn (P0) (7 WT and 7 Brd1\(^{+/–}\)) and frontal cortex from juvenile (P21) (6 WT and 6 Brd1\(^{+/–}\)) male mice by free-hand dissection. An overview of RNA extraction, quality control, cDNA synthesis, and qPCR protocols can be found in Table S1. Primers were designed to span exon boundaries to avoid amplification of potential contaminating genomic DNA (Table S2). Relative gene expression was calculated by the “standard curve method”\(^39\) using serial dilutions of a pool of cDNA form all samples as a standard. The expression stability of reference genes (n = 4) within and between

---

**Figure 3.** Comparison of group mean difference in volume of subcortical structures in ENIGMA SZ samples and Brd1\(^{+/–}\) mice. *Marks structures in which mean groupwise volume differ significantly between SZ patients and controls. *Marks structures in which mean groupwise volume differ significantly between Brd1\(^{+/–}\) and WT mice. In mice, caudate and putamen are not anatomically distinct and are referred to as the caudate-putamen\(^61\).
experimental groups was determined by analyzing their relative mRNA levels with the Normfinder software. mRNA levels were normalized to the geometric mean of the mRNA levels of the two genes selected as the best combination for normalization.

**Statistical analysis.** MRI, stereological and mRNA data were analyzed using the GraphPad Prism software (San Diego, USA) and Microsoft Excel 2016 (Redmond, Washington, USA). Data were checked for normal distribution by the Shapiro-Wilk normality test. The statistical significance of group wise comparisons were determined by the student's t-test. Correlation coefficients were calculated using the Correlation data analysis tool in the Microsoft Excel Real Statistics add-on package. Differences in cortical thickness were assessed at each point on the atlas cortical surface using two-sample t-tests. Only uncorrected p values are presented. The resulting maps were thresholded at p < 0.05. For assessment of neuronal loss across cortical layers, a two-way ANOVA with genotype and layer as factors. Tukey's test was performed as post hoc test and Bonferroni's corrected p value reported. Data were presented as mean ± SEM, and p values < 0.05 were considered to be statistically significant. Details on the statistic applied in CSEA can be found in (2), where the method is described in detail. Briefly, the overlap of genes identified as differentially expressed between Brd1−/− and WT mice and genes highly enriched in certain cell types was compared and a p value for Fisher's Exact Test is provided. Only cell type specific genes determined with the highest stringencies for enrichment (Psi = 0.0001) were used in this study and only Benjamini Hochberg corrected p-value (q value) < 0.05 were considered significant.

**References**

1. van Erp, T. G. M. et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol. Psychiatry* 21, 547–53 (2016).
2. McGrath, J. et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med.* 2, 13 (2004).
3. Riche, S. et al. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511, 421–427 (2014).
4. Paridinas, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and maintained by background selection (2016).
5. Contestabile, A. & Sintoni, S. Histone acetylation in neurodevelopment. *Curr. Pharm. Des.* 19, 5043–50 (2013).
6. Ibi, D. & Gonzalez-Maeso, J. Epigenetic signaling in schizophrenia. *Cell. Signal.* 27, 2131–6 (2015).
7. Mishima, Y. et al. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. *Blood* 118, 2443–53 (2011).
8. Fryland, T. et al. Identification of the BRD1 interaction network and its impact on mental disorder risk. *Genome Med.* 8, 53 (2016).
9. Severinsen, J. et al. Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorder. *Mol. Psychiatry* 11, 1126–38 (2006).
10. Nyegaard, M. et al. Support of association between BRD1 and both schizophrenia and bipolar affective disorder. *American J. Med. Genet. Part B, Neuropsychiatr. Genet. Off. J. Int. Soc. Psychiatr. Genet.* 153B, 582–91 (2010).
11. Aberg, K. A. et al. A comprehensive family-based replication study of schizophrenia genes. *JAMA Psychiatry* 70, 1–9 (2013).
12. Andreasen, O. A., Thompson, W. K. & Dale, A. M. Boosting the power of schizophrenia genetics by leveraging new statistical tools. *Schizophr. Bull.* 40, 13–17 (2014).
13. Purcell, S. M. et al. A polygenic burden of rare disruptive mutations in schizophrenia. *Nature* 506, 185–90 (2014).
14. Qvist, P. et al. Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia. *Neurobiol. Learn. Mem.* 141, 44–52 (2017).
15. Qvist, P. et al. The Schizophrenia-Associated BRD1 Gene Regulates Behavior, Neurotransmission, and Expression of Schizophrenia Risk Enriched Gene Sets in Mice. * Biol. Psychiatry 82, 62–76 (2017).*
16. Hartig, W., Brauer, K. & Brückner, G. Wisteria floribunda agglutinin-labelled nets surround parvalbumin-containing neurons. *Neuroreport* 3, 869–72 (1992).
17. Celio, M. R. & Blümcke, I. Perineuronal nets—a specialized form of extracellular matrix in the adult nervous system. *Brain Res. Brain Res. Rev.* 19, 128–45 (1994).
18. Fusar-Poli, P. et al. Neuroanatomy of vulnerability to psychosis: A voxel-based meta-analysis. *Neurosci. Biobehav. Rev.* 35, 1175–1185 (2011).
19. Hajima, S. V. et al. Brain Volumes in Schizophrenia: A Meta-Analysis: Data. *Schizophr. Bull.* 39, 1129–1138 (2013).
20. Olabi, B. et al. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. *Biol. Psychiatry* 70, 88–96 (2011).
21. Vita, A., De Peri, L., Deste, G. & Sacchetti, E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. *Transl. Psychiatry* 2, e190 (2012).
22. Okada, N. et al. Abnormal asymmetries in subcortical brain volume in schizophrenia. *Mol. Psychiatry* 21, 1460–1466 (2016).
23. Kreczmannski, P. et al. Volume, neuron density and total neuron number in five subcortical regions in schizophrenia. *Brain 130*, 678–92 (2007).
24. Garey, L. When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits. *J. Anat.* 217, 324–333 (2010).
25. Kochunov, P. & Hong, L. E. Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. *Schizophr. Bull.* 40, 721–8 (2014).
26. Meyer-Lindenberg, A. Neuroimaging and the question of neurodegeneration in schizophrenia. *Prog. Neurobiol.* 95, 514–6 (2011).
27. Birur, B., Kraguljac, N. V., Shelton, R. C. & Lahti, A. C. Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder—a systematic review of the magnetic resonance neuroimaging literature. *npj Schizophr. Biol.* 3, 15 (2017).
28. Song, C. et al. Increased Intrinsic Brain Activity in the Striatum Reflects Symptom Dimensions in Schizophrenia. *Schizophr. Bull.* 39, 387–395 (2013).
29. Graham, J. A., Parkinson, J. A. & Owen, A. M. The cognitive functions of the caudate nucleus. *Prog. Neurobiol.* 86, 141–155 (2008).
30. Do, J., Kim, J.-I., Bakes, J., Lee, K. & Kang, B.-K. Functional roles of neurotransmitters and neuromodulators in the dorsal striatum. *Learn. Mem.* 20, 21–28 (2012).
31. Calipari, E. S., Huggins, K. N., Mathews, T. A. & Jones, S. R. Conserved dorsal–ventral gradient of dopamine release and uptake rate in mice, rats and rhesus macaques. *Neurochem. Int.* 61, 986–991 (2012).
32. Wu, Y. & Parent, A. Striatal interneurons expressing calretinin, parvalbumin or NADPH-diaphorase: a comparative study in the rat, monkey and human. *Brain Res.* 863, 182–91 (2000).
33. Gonzales, K. K. & Smith, Y. Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions. *Ann. N. Y. Acad. Sci.* 1349, 1–45 (2015).
34. Gerfen, C. R. & Surmeier, D. J. Modulation of striatal projection systems by dopamine. *Annu. Rev. Neurosci.* 34, 441–66 (2011).
35. Ganganos, G. et al. Spatial distribution of D1R- and D2R-expressing medium-sized spiny neurons differs along the rostro-caudal axis of the mouse dorsal striatum. *Front. Neural Circuits* 7 (2013).
36. Maurice, N. et al. Striatal Cholinergic Interneurons Control Motor Behavior and Basal Ganglia Function in Experimental Parkinsonism. *Cell Rep.* 13, 657–666 (2015).
37. Tepper, J. M. & Bolam, J. P. Functional diversity and specificity of neostriatal interneurons. *Curr. Opin. Neurobiol.* 14, 685–92 (2004).
38. Robertson, G. S., Vincent, S. R. & Fibiger, H. C. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. *Neuroscience* 49, 285–96 (1992).
39. Deniau, J. M., Maillaux, P., Maurice, N. & Charpier, S. The pars reticulata of the substantia nigra: a window to basal ganglia output. *Prog. Brain Res.* 160, 151–72 (2007).
40. Kravitz, A. V. et al. Regulation of parkinsonian motor behaviours by optogenetic modulation of basal ganglia circuitry. *Nature* 466, 622–6 (2010).
41. Lüthi, A. & Lüscher, C. Pathological circuit function underlying addiction and anxiety disorders. *Nat. Neurosci.* 17, 1635–1643 (2014).
42. Weinberger, D. R. & Berman, K. F. Prefrontal function in schizophrenia: confounds and controversies. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* 351, 1495–503 (1996).
43. Baas, D. et al. Evidence of altered cortical and amygdala activation during social decision-making in schizophrenia. *Neuroimage* 40, 719–27 (2008).
44. Meyer-Lindenberg, A. et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. *Nat. Neurosci.* 5, 267–271 (2002).
45. Allen, P. et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. *Schizophr. Bull.* 38, 1268–76 (2012).
46. Murray, A. J. et al. Parvalbumin-positive interneurons of the prefrontal cortex support working memory and cognitive flexibility. *Sci. Rep.* 5, 16778 (2015).
47. Larsen, D. D. Retrograde tracing with recombinant rabies virus reveals correlations between projection targets and dendritic architecture in layer 5 of mouse barrel cortex. *Front. Neural Circuits* 1 (2008).
48. Hattox, A. M. & Nelson, S. B. Layer V Neurons in Mouse Cortex Projecting to Different Targets Have Distinct Physiological Properties. *J. Neurophysiol.* 98, 3330–3340 (2007).
49. Shepherd, G. M. G. Diversity and complexity in the pyramidal tract projectome. *Nat. Rev. Neurosci.* 15, 63 (2014).
50. Kjaervo, M., McKellar, H. & Gogos, J. A. Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models. *Neuroscience* 211, 136–164 (2012).
51. Slod, J. G., Zijdenbos, A. P. & Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. *IEEE Trans. Med. Imaging* 17, 87–97 (1998).
52. Coupé, P. et al. An optimized blockwise nonlocal means denoising filter for 3-D magnetic resonance images. *IEEE Trans. Med. Imaging* 27, 425–43 (2008).
53. Yushkevich, P. A. et al. User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability. *Neuroimage* 31, 1116–1126 (2006).
54. Avants, B. B., Epstein, C. L., Grossman, M. & Gee, J. C. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. *Med. Image Anal.* 12, 26–41 (2008).
55. Dorr, A. E., Lerch, J. P., Spring, S., Kabani, N. & Henkelman, R. M. High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. *Neuroimage* 42, 60–9 (2008).
56. Lerch, J. P. et al. Cortical thickness measured from MRI in the YAC128 mouse model of Huntington’s disease. *Neuroimage* 41, 243–251 (2008).
57. Dougherty, J. D., Schmidt, E. F., Nakajima, M. & Heintz, N. Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. *Nucleic Acids Res.* 38, 4218–30 (2010).
58. Holmgård, A. et al. In Vivo Knockout of the Vegfa Gene by Lentiviral Delivery of CRISPR/Cas9 in Mouse Retinal Pigment EpitheliumCells. *Mol. Ther. Nucleic Acids* 9, 89–99 (2017).
59. Heid, C. A., Stevens, J., Livak, K. J. & Williams, P. M. Real time quantitative PCR. *Genome Res.* 6, 986–994 (1996).
60. Andersen, C. L., Jensen, J. L. & Orntoft, T. F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. *Cancer Res.* 64, 5245–50 (2004).
61. Mitchell, I. J., Cooper, A. J. & Griffiths, M. R. The selective vulnerability of striatopallidal neurons. *Prog. Neurobiol.* 59, 691–719 (1999).

**Acknowledgements**

The study was supported by grants from the Danish Council for Independent Research—Medical Sciences (ADB and JHC), The Augustinus Foundation (JHC), The Risfors Foundation (JHC), The Lundbeck Foundation (ADB), The Faculty of Health Sciences, Aarhus University (ADB), and The Novo Nordisk Foundation (ADB and JHC). Centre for Stochastic Geometry and Advanced Bioimaging was supported by Villum Foundation (JRN). We thank Tanja Stenshøj Östergaard for the genotyping of mice and Helene M. Anderssen and Maj-Britt Lundorf for assisting in histology and immunohistochemistry experiments.

**Author Contributions**
P.Q., A.D.B. and J.H.C. designed and directed the experiments. P.Q. wrote the manuscript. J.H.C. and G.W. managed the breeding of the mice. B.H., S.R. and H.S.J. conducted and managed MRI experiments and SFE performed the analysis of MRI data. M.B. performed immunostaining under the supervision of J.R.N., T.J.C., S.M. and S.G. J.R. and M.B. performed qPCR studies while data was analyzed by V.P. and P.Q. P.Q. analyzed RNAseq data. P.Q. and J.R.N. designed and conducted stereological studies. P.Q. and S.F.E. performed the statistical analyses. P.Q., O.M., A.D.B. and J.H.C. designed and directed the study.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-018-34729-5.

**Competing Interests:** A.D.B. and O.M. are coinventors on a patent application submitted by Aarhus University entitled “Method for diagnosis and treatment of a mental disease” (EP20060742417) that includes claims relating to *BRD1* among other genes. A.D.B., J.H.C., GW, and P.Q. are coinventors on a patent application submitted by Capnova A/S entitled “Genetically modified non-human mammal and uses thereof” (PCT/EP2013/069524) that includes the *Brd1* C−/− mouse. S.F.E., B.H., M.B., S.R., J.R., VP, S.M., T.J.C., H.S.J., S.G., J.R.N. report no biomedical financial interests or potential conflicts of interest.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018